Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Non-Current Assets (2017 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Other Non-Current Assets for 7 consecutive years, with $8.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 2113.01% to $8.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.2 million, a 2113.01% increase, with the full-year FY2025 number at $8.2 million, up 2113.01% from a year prior.
  • Other Non-Current Assets was $8.2 million for Q4 2025 at Iovance Biotherapeutics, down from $9.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $66.4 million in Q4 2023 to a low of $282000.0 in Q3 2023.
  • A 3-year average of $17.0 million and a median of $6.4 million in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: crashed 99.44% in 2024, then soared 2113.01% in 2025.
  • Iovance Biotherapeutics' Other Non-Current Assets stood at $66.4 million in 2023, then plummeted by 99.44% to $369000.0 in 2024, then skyrocketed by 2113.01% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Other Non-Current Assets are $8.2 million (Q4 2025), $9.3 million (Q3 2025), and $5.9 million (Q2 2025).